Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences Q1 revenue rises 3.7%, but cuts 2025 adjusted EPS guidance

Negative Impact 4 of 5 earnings Written later

Integra LifeSciences reported first-quarter 2025 results on May 5, 2025. Reported revenue rose 3.7% to $382.7 million, but organic revenue fell 3.5%, the GAAP net loss widened to $25.3 million, and adjusted earnings per diluted share fell to $0.41 from $0.55. The company reaffirmed its full-year revenue guidance but cut its full-year adjusted EPS guidance to $2.19 to $2.29, including an estimated $(0.22) per share impact from new tariffs.

Key points

  • Q1 revenue was $382.7 million, up 3.7% on a reported basis and down 3.5% on an organic basis.
  • GAAP net loss was $25.3 million, or $(0.33) per diluted share, versus a $3.3 million loss, or $(0.04), a year earlier.
  • Adjusted EPS was $0.41 versus $0.55; full-year adjusted EPS guidance was cut to $2.19 to $2.29.
  • Full-year 2025 revenue guidance of $1.650 billion to $1.715 billion was reaffirmed; second-quarter adjusted EPS is expected at $0.40 to $0.45.

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECMay 5, 2025, 6:45 AM ET
Accession number0000917520-25-000038

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:59 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 05, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.